Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 97 filers reported holding Y-MABS THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 0.02 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $270 | -21.7% | 22,279 | +5.3% | 0.00% | – |
| Q1 2024 | $345 | +159.4% | 21,158 | +8.5% | 0.00% | – |
| Q4 2023 | $133 | +33.0% | 19,501 | +6.7% | 0.00% | – |
| Q3 2023 | $100 | -20.0% | 18,282 | 0.0% | 0.00% | – |
| Q2 2023 | $125 | +0.8% | 18,282 | -26.1% | 0.00% | – |
| Q1 2023 | $124 | +44.2% | 24,723 | +40.3% | 0.00% | – |
| Q4 2022 | $86 | -100.0% | 17,623 | +5.5% | 0.00% | – |
| Q3 2022 | $241,000 | +10.6% | 16,708 | +15.8% | 0.00% | – |
| Q2 2022 | $218,000 | +29.8% | 14,423 | +1.8% | 0.00% | – |
| Q1 2022 | $168,000 | -99.2% | 14,165 | -98.3% | 0.00% | -100.0% |
| Q3 2019 | $21,833,000 | +27.6% | 837,800 | +12.0% | 0.00% | +50.0% |
| Q2 2019 | $17,115,000 | +2.0% | 748,351 | +16.9% | 0.00% | 0.0% |
| Q1 2019 | $16,782,000 | +111.8% | 640,297 | +64.4% | 0.00% | +100.0% |
| Q4 2018 | $7,922,000 | -23.4% | 389,497 | +0.0% | 0.00% | -50.0% |
| Q3 2018 | $10,342,000 | – | 389,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sofinnova Investments, Inc. | 2,194,278 | $84,238,000 | 6.25% |
| Burrage Capital Management LLC | 123,025 | $4,723,000 | 3.73% |
| MPM BioImpact LLC | 337,291 | $12,949,000 | 3.12% |
| First Light Asset Management, LLC | 608,193 | $23,349,000 | 2.39% |
| Cormorant Asset Management, LP | 1,397,700 | $53,658,000 | 2.06% |
| SPHERA FUNDS MANAGEMENT LTD. | 396,521 | $15,222,000 | 1.50% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 801 | $33,000 | 0.61% |
| Artal Group S.A. | 285,028 | $10,942,000 | 0.27% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 298,213 | $11,448,000 | 0.24% |
| Virtus ETF Advisers LLC | 7,309 | $281,000 | 0.15% |